Aptamers Market Research Report-Forecast till 2030

Aptamers Market by Type (Nucleic Acid and Peptide Aptamers), Application (Diagnostics, Therapeutics Development), Technology (Selex, X-aptamer and MARAS technique), End Users (Biotechnology and Pharmaceutical Companies)- Forecast till 2030

ID: MRFR/LS/5167-HCR | 85 Pages | Published By Kinjoll Dey on March 2023         

Aptamers Market Speak to Analyst Request a Free Sample

Aptamers Market

Aptamers Market will grow at CAGR of 18.10% to hit USD 1,724.5 million by 2030

By Type Nucleic Acid Peptide Aptamers
By Application Diagnostics Therapeutics Development
By Technology Selex X-aptamer MARAS technique
By End Users Biotechnology Pharmaceutical Companies
Key Players
Companies Profiled   Aptamer Sciences   Aptagen   LLC   Base Pair Biotechnologies   Ophthotech Corporation   Am Biotechnologies   Aptamer Solutions Ltd   Aptus Biotech S.L   Neoventures Biotechnology Inc   Somalogic   Trilink Biotechnologies
Market Driving Forces   Increasing R&D expenditure and constant technological advances
Request a Free Sample

Aptamers Market Overview:

During the forecast period (2022–2030), the Aptamers Market is expected to grow at a significant CAGR of 18.10 percent. Aptamers are peptide compounds with high selectivity for binding to the targeted lipid, protein, or nucleic acid components. These are produced quickly and used in protein inhibition, specific detection, and characterization. With antibodies, small compounds, and other aptamers, aptamers can be employed as detection reagents, pharmacological leads, and functional proteomic levels.

Aptamers can be changed to have increased affinity and specificity to a large range of targets. Improvements in aptamer development methods, rising R&D spending, and a growing number of firms participating in this industry are some of the significant drivers driving market expansion. They're chemically manufactured, so there's no batch-to-batch variance and development takes less time. Continuous technological advancements are also projected to support growth.


The Global Aptamers Market has been segmented on the basis of type, application, technology and end users.

On the basis of type, the market has been classified as nucleic acid aptamers and peptide aptamers. The nucleic acid aptamers have been segmented into DNA-Based Aptamers, RNA-Based Aptamers.

On the basis of application, the market has been classified as diagnostics, therapeutics development, research and development, other applications

On the basis of technology, the market has been classified as Selex, X-aptamer and MARAS technique.

On the basis of end users, the market has been classified as academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations and other end users

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European aptamers market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The aptamers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Aptamers Market Share, by Region, 2017 (%)

Global Aptamers Market Share, by Region, 2017 (%)

Source: MRFR Analysis

In the aptamers market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies and high investment and funding to support the development of aptamers. The other factor such as the growing demand for aptamer therapeutics coupled with a rise in a number of research laboratories helps to boost the market.

The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. The increasing number of small-scale start-ups, government organizations, rising number of products under clinical investigation, and growing number of academic research laboratories investigating the potential of aptamers are anticipated to support future growth of this market.

Whereas the market share in the Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.

The market in the Middle East & Africa is expected to account for the smallest share of the global aptamers market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.Recent Development

Aptus Biotech is a biotech startup with the objective of becoming a leader in the creation of novel biotechnological applications using aptamers. The Ramon y Cajal Foundation, which has vast expertise in research and biomedical applications, supports Aptus management and technical staff. APTUS Biotech provides aptamer selection services such as oligonucleotide selection using the SELEX method, aptamer storage by bacterial insertion, chemical production of aptamers, and target protein binding investigations.

Following the failure of two phases III clinical trials (OPH1002 and OPH1003) of Ophthotech's proprietary anti-platelet-derived growth factor (anti-PDGF) drug, Fovista, in combination with Regeneron's Eylea (aflibercept) or Genentech's Avastin (bevacizumab) for the treatment of wet age-related macular degeneration, the company announced this week that the last Phase III clinical trial (OPH100 Fovista, on the other hand, is not the only medicine in Ophthotech's AMD pipeline. Zimura (avacincaptad pegol), a complement 5 (C5) inhibitor, is being developed by the business for the treatment of wAMD and geographic atrophy (GA), a type of dry AMD (dAMD).

Key Players

  • Aptamer Sciences, Inc

  • Aptagen

  • LLC

  • Base Pair Biotechnologies, Inc

  • Ophthotech Corporation

  • Am Biotechnologies

  • Aptamer Solutions Ltd

  • Aptus Biotech S.L

  • Neoventures Biotechnology Inc

  • Somalogic, Inc

  • Trilink Biotechnologies, Inc

  • Vivonics, Inc

  • Noxxon Pharma

Global Aptamers Market, by Type

  • Nucleic acid aptamers

  • DNA-Based Aptamers

  • RNA-Based Aptamers

  • Peptide aptamers

Global Aptamers Market, by Application

  • Diagnostics

  • Therapeutics development

  • Research and development

  • Other applications

Global Aptamers Market, by Technology

  • Selex

  • X-aptamer

  • MARAS technique

Global Aptamers Market, by End Users

  • Academic and government research institutes

  • Biotechnology and pharmaceutical companies

  • Contract research organizations

  • Other end users

Global Aptamers Market, by Region

  • Americas

    • North America

      • US

      • Canada

    • South America

  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Intended Audience

  • Manufacturers and distributors

  • Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)

  • Research institutes

  • Contract manufacturing organizations (CMOs)

  • Government associations

  • Market research and consulting firms

  • Venture capitalists and investors

Report Scope:

Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2020-2030: 18.10%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Application, Technology And End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Aptamer Sciences, Inc., Aptagen, LLC, Base Pair Biotechnologies, Inc., Ophthotech Corporation, Am Biotechnologies, LLC, Aptamer Solutions Ltd., Aptus Biotech S.L., Neoventures Biotechnology Inc., Somalogic, Inc., Trilink Biotechnologies, Inc., Vivonics, Inc., Noxxon Pharma
  Key Market Opportunities

  • Rising number of products under clinical investigation
  • Growing number of academic research laboratories investigating
  •   Key Market Drivers   Increasing R&D expenditure and constant technological advances

    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The aptamers market is projected to grow at a 18.10% CAGR between 2020-2030.

    North America is projected to command the largest share in the aptamers market.

    It is widely used in research and development, therapeutics development, and diagnostics.

    Increasing R&D expenditure and constant technological advances are adding market growth.

    Inadequate regulatory structure may limit market growth.